Drug Repositioning-Based Drug Development

A technology for developing first-in-class anticancer therapeutics with novel mechanisms of action, based on a drug repositioning strategy.

BSP series

1First-in-class anticancer drug targeting cancer cell metabolic pathways

2Induces selective metabolic stress in cancer cells through target enzyme elevation and NAD+ depletion

3Ensures low toxicity and superior safety profile as normal cells naturally metabolize the compound

4Mechanism of action (MoA) elucidated in Triple-Negative Breast Cancer (TNBC) cell lines (MDA-MB-231)